LT4011908T - Itin ilgai veikiantys insulino-fc sulieti baltymai ir naudojimo būdai - Google Patents

Itin ilgai veikiantys insulino-fc sulieti baltymai ir naudojimo būdai

Info

Publication number
LT4011908T
LT4011908T LTEP21207279.7T LT21207279T LT4011908T LT 4011908 T LT4011908 T LT 4011908T LT 21207279 T LT21207279 T LT 21207279T LT 4011908 T LT4011908 T LT 4011908T
Authority
LT
Lithuania
Prior art keywords
methods
fusion proteins
acting insulin
extra long
extra
Prior art date
Application number
LTEP21207279.7T
Other languages
English (en)
Inventor
Thomas M. Lancaster
Todd C. Zion
Original Assignee
Akston Biosciences Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akston Biosciences Corporation filed Critical Akston Biosciences Corporation
Publication of LT4011908T publication Critical patent/LT4011908T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
LTEP21207279.7T 2018-06-29 2019-06-28 Itin ilgai veikiantys insulino-fc sulieti baltymai ir naudojimo būdai LT4011908T (lt)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201862692507P 2018-06-29 2018-06-29
US201862692498P 2018-06-29 2018-06-29
US201862693814P 2018-07-03 2018-07-03
US201862696645P 2018-07-11 2018-07-11
US201862698648P 2018-07-16 2018-07-16
US201862702167P 2018-07-23 2018-07-23
US201862719347P 2018-08-17 2018-08-17
US201862740735P 2018-10-03 2018-10-03
US201862743358P 2018-10-09 2018-10-09
US201862774682P 2018-12-03 2018-12-03
US201862781378P 2018-12-18 2018-12-18
US201862781368P 2018-12-18 2018-12-18
US201962824176P 2019-03-26 2019-03-26
US201962827809P 2019-04-01 2019-04-01
US201962837188P 2019-04-22 2019-04-22

Publications (1)

Publication Number Publication Date
LT4011908T true LT4011908T (lt) 2023-09-11

Family

ID=68985236

Family Applications (4)

Application Number Title Priority Date Filing Date
LTEP21207279.7T LT4011908T (lt) 2018-06-29 2019-06-28 Itin ilgai veikiantys insulino-fc sulieti baltymai ir naudojimo būdai
LTEP22203969.5T LT4186920T (lt) 2018-06-29 2019-06-28 Itin ilgai veikiantys insulino-fc sulieti baltymai ir naudojimo būdai
LTEP21164434.9T LT3892628T (lt) 2018-06-29 2019-06-28 Itin ilgai veikiantys insulino-fc sulieti baltymai ir naudojimo būdai
LTEPPCT/US2019/040010T LT3655006T (lt) 2018-06-29 2019-06-28 Itin ilgai veikiantys insulino-fc sulieti baltymai ir naudojimo būdai

Family Applications After (3)

Application Number Title Priority Date Filing Date
LTEP22203969.5T LT4186920T (lt) 2018-06-29 2019-06-28 Itin ilgai veikiantys insulino-fc sulieti baltymai ir naudojimo būdai
LTEP21164434.9T LT3892628T (lt) 2018-06-29 2019-06-28 Itin ilgai veikiantys insulino-fc sulieti baltymai ir naudojimo būdai
LTEPPCT/US2019/040010T LT3655006T (lt) 2018-06-29 2019-06-28 Itin ilgai veikiantys insulino-fc sulieti baltymai ir naudojimo būdai

Country Status (15)

Country Link
US (9) US10961294B2 (lt)
EP (5) EP4011908B1 (lt)
JP (2) JP7417277B2 (lt)
KR (2) KR20210029210A (lt)
CN (2) CN113038964B (lt)
AU (2) AU2019291945B2 (lt)
BR (1) BR112020026777A2 (lt)
CA (1) CA3104144A1 (lt)
DK (4) DK4011908T5 (lt)
FI (2) FI4186920T3 (lt)
HR (4) HRP20220091T1 (lt)
HU (4) HUE058005T2 (lt)
LT (4) LT4011908T (lt)
SI (4) SI3892628T1 (lt)
WO (1) WO2020006529A1 (lt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3551209T1 (sl) 2016-12-09 2021-10-29 Akston Biosciences Corp Inzulin-FC fuzije in postopki uporabe
WO2019035010A1 (en) 2017-08-15 2019-02-21 Kindred Biosciences, Inc. IGG VARIANTS FOR VETERINARY USE
LT4011908T (lt) 2018-06-29 2023-09-11 Akston Biosciences Corporation Itin ilgai veikiantys insulino-fc sulieti baltymai ir naudojimo būdai
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
WO2021011827A1 (en) * 2019-07-16 2021-01-21 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
AU2020407365B2 (en) 2019-12-19 2023-09-21 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
KR102898622B1 (ko) 2020-04-10 2025-12-12 악스톤 바이오사이언시스 코퍼레이션 Covid-19 융합 단백질에 대한 항원 특이적 면역요법 및 사용 방법
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
WO2022017309A1 (zh) * 2020-07-24 2022-01-27 江苏晟斯生物制药有限公司 胰岛素-Fc融合蛋白及其应用
AU2021401635A1 (en) * 2020-12-14 2023-06-22 Eli Lilly And Company Methods of treating diabetes
US11667689B2 (en) 2021-07-23 2023-06-06 Akston Biosciences Corporation Insulin-Fc fusion proteins and methods of use to treat cancer
WO2023064711A2 (en) * 2021-10-14 2023-04-20 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
AR127619A1 (es) 2021-11-15 2024-02-14 Lilly Co Eli FORMULACIONES CONSERVADAS DE FUSIONES DE INSULINA-Fc
KR20240158331A (ko) * 2022-03-16 2024-11-04 베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 인간 인슐린 유사체, 이의 융합 단백질 및 의약적 용도
CN119403824A (zh) * 2022-06-23 2025-02-07 赛诺菲 单链胰岛素及其Fc缀合物
WO2025198855A1 (en) * 2024-03-21 2025-09-25 Akston Biosciences Corporation Pd-l1 analog fusion proteins for antigen specific immunotherapy and methods of use

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030040601A1 (en) 2001-06-08 2003-02-27 Ivan Diers Method for making insulin precursors and insulin analog precursors
US7169894B2 (en) * 2001-11-14 2007-01-30 Mirari Biosciences, Inc. Methods and compositions for reverse translation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20100143479A1 (en) 2008-12-04 2010-06-10 Oakwood Laboratories, Llc Method of making sustained release microparticles
EP2408470A4 (en) 2009-03-20 2012-08-29 Smartcells Inc SOLUBLE NONDEPOT INSULIN CONJUGATE AND ITS USE
US20120093814A1 (en) * 2009-03-30 2012-04-19 Boehringer Ingelheim International Gmbh Fusion Proteins Comprising Canine FC Portions
CN101891823B (zh) 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 一种Exendin-4及其类似物融合蛋白
CA2805739A1 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
US9074015B2 (en) * 2010-07-28 2015-07-07 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
AR087433A1 (es) 2011-08-08 2014-03-26 Merck Sharp & Dohme Analogos de insulina n-glicosilados
WO2013074598A1 (en) * 2011-11-18 2013-05-23 Merck Sharp & Dohme Corp. Fc CONTAINING POLYPEPTIDES HAVING INCREASED ANTI-INFLAMMATORY PROPERTIES AND INCREASED FcRN BINDING
KR102041412B1 (ko) 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
CN103509118B (zh) * 2012-06-15 2016-03-23 郭怀祖 胰岛素-Fc融合蛋白
AU2013302569B2 (en) * 2012-08-17 2017-09-28 Dresser-Rand Company System and method for detecting stall or surge in radial compressors
WO2014093387A1 (en) * 2012-12-10 2014-06-19 Kindred Biosciences, Inc. Vegf receptor fusion proteins for veterinary use
MY186990A (en) 2013-02-26 2021-08-26 Hanmi Pharm Ind Co Ltd Novel insulin analog and use thereof
US10287336B2 (en) 2014-09-18 2019-05-14 AskGene Pharma, Inc. Feline erythropoietin receptor agonists
US10392429B2 (en) 2014-10-06 2019-08-27 Case Western Reserve University Biphasic single-chain insulin analogues
CA2964918A1 (en) 2014-10-20 2016-04-28 Case Western Reserve University Halogenated insulin analogues of enhanced biological potency
US10822386B2 (en) 2014-12-24 2020-11-03 Case Western Reserve University Insulin analogues with enhanced stability and reduced mitogenicity
JP2018505874A (ja) 2015-01-20 2018-03-01 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎ Ｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 選択的シグナリング特性及びより低い分裂促進性を有するインスリンアナログ
AU2016212707A1 (en) * 2015-01-29 2017-08-10 Nexvet Australia Pty Ltd Therapeutic and diagnostic agents
EP3260139A4 (en) 2015-02-17 2018-09-05 Hanmi Pharm. Co., Ltd. Long-acting insulin or insulin analogue complex
MX379136B (es) * 2015-05-04 2025-03-10 Apogenix Ag Proteinas agonistas receptoras cd40 de cadena sencilla.
AR105616A1 (es) * 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
CN107743494B (zh) 2015-06-02 2022-04-29 诺和诺德股份有限公司 具有极性重组延伸体的胰岛素
EP3757117A1 (en) 2015-11-16 2020-12-30 Ubiprotein, Corp. A method for extending half-life of a protein
CN109071623B (zh) * 2016-05-04 2022-05-27 美国安进公司 用于扩增t调节性细胞的白细胞介素-2突变蛋白
EP3481413A4 (en) * 2016-07-08 2020-01-08 Askgene Pharma, Inc. FUSION PROTEIN WITH LEPTIN AND METHOD FOR THE PRODUCTION AND USE THEREOF
AU2017298565B2 (en) 2016-07-22 2021-08-19 The Walter And Eliza Hall Institute Of Medical Research Insulin analogs
BR112019005637A2 (pt) * 2016-09-23 2019-07-30 Hanmi Pharm Ind Co Ltd análogos da insulina com afinidade reduzida para o receptor de insulina e seu uso
CN110114369A (zh) 2016-10-17 2019-08-09 威隆股份公司 修饰的抗体恒定区
SI3551209T1 (sl) 2016-12-09 2021-10-29 Akston Biosciences Corp Inzulin-FC fuzije in postopki uporabe
UY37629A (es) 2017-03-07 2018-10-31 Univ Case Western Reserve Análogos de insulina de cadena simple estabilizados por un cuarto puente disulfuro
US10572594B2 (en) 2017-08-01 2020-02-25 Intuit Inc. Extracting domain-specific actions and entities in natural language commands recognized based on edition and recognition scores
WO2019035010A1 (en) 2017-08-15 2019-02-21 Kindred Biosciences, Inc. IGG VARIANTS FOR VETERINARY USE
US20210214412A1 (en) 2018-04-16 2021-07-15 University Of Utah Research Foundation Glucose-responsive insulin
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
LT4011908T (lt) 2018-06-29 2023-09-11 Akston Biosciences Corporation Itin ilgai veikiantys insulino-fc sulieti baltymai ir naudojimo būdai
EP3856760A1 (en) 2018-09-25 2021-08-04 AbSci, LLC Protein purification methods
MA53809A (fr) 2018-10-05 2022-01-12 Novo Nordisk As Composés bifonctionnels comprenant des peptides d'insuline et des peptides d'egf(a)
WO2020106748A1 (en) 2018-11-19 2020-05-28 Case Western Reserve University Single-chain insulin analogues with poly-alanine c-domain sub-segments
US20220235111A1 (en) 2019-05-17 2022-07-28 Case Western Reserve University Variant Single-Chain Insulin Analogues
WO2021011827A1 (en) 2019-07-16 2021-01-21 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
TWI844709B (zh) 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
AU2020407365B2 (en) 2019-12-19 2023-09-21 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use

Also Published As

Publication number Publication date
CN113038964A (zh) 2021-06-25
FI4186920T3 (fi) 2024-03-20
US20240101635A1 (en) 2024-03-28
AU2019291945A1 (en) 2021-01-14
WO2020006529A1 (en) 2020-01-02
CN113038964B (zh) 2025-05-27
HUE058005T2 (hu) 2022-06-28
KR20210029210A (ko) 2021-03-15
DK4011908T5 (da) 2024-08-12
KR20250139414A (ko) 2025-09-23
DK3892628T3 (da) 2022-11-14
LT3655006T (lt) 2022-03-10
EP3655006A4 (en) 2021-01-13
US11673934B2 (en) 2023-06-13
JP2021530210A (ja) 2021-11-11
SI4186920T1 (sl) 2024-05-31
EP4186920A1 (en) 2023-05-31
DK4186920T3 (da) 2024-03-25
HRP20221418T1 (hr) 2023-01-06
HRP20240408T1 (hr) 2024-06-07
US20200231646A1 (en) 2020-07-23
EP4011908B1 (en) 2023-06-07
EP4344738A2 (en) 2024-04-03
EP3892628B1 (en) 2022-09-07
CN120665204A (zh) 2025-09-19
DK4011908T3 (da) 2023-08-07
EP4011908A1 (en) 2022-06-15
US20220017590A1 (en) 2022-01-20
FI4011908T3 (fi) 2023-08-04
JP7510728B2 (ja) 2024-07-04
EP4186920B1 (en) 2024-01-03
DK4186920T5 (da) 2024-07-22
AU2019291945B2 (en) 2024-11-14
US20200157170A1 (en) 2020-05-21
AU2024287186A1 (en) 2025-01-23
HUE065725T2 (hu) 2024-06-28
US20200157169A1 (en) 2020-05-21
SI3655006T1 (sl) 2022-04-29
SI4011908T1 (sl) 2023-10-30
HUE060471T2 (hu) 2023-03-28
LT3892628T (lt) 2022-12-12
US10947292B2 (en) 2021-03-16
US20200407413A1 (en) 2020-12-31
US11773151B2 (en) 2023-10-03
EP3655006B1 (en) 2021-11-17
US20250289863A1 (en) 2025-09-18
HRP20220091T1 (hr) 2022-04-15
EP3892628A1 (en) 2021-10-13
CA3104144A1 (en) 2020-01-02
HUE062719T2 (hu) 2023-11-28
SI3892628T1 (sl) 2023-01-31
BR112020026777A2 (pt) 2021-03-30
US10851147B2 (en) 2020-12-01
EP4344738A3 (en) 2024-05-22
DK3655006T3 (da) 2022-02-21
US11261229B2 (en) 2022-03-01
US10961294B2 (en) 2021-03-30
US10870686B2 (en) 2020-12-22
US20220009990A1 (en) 2022-01-13
US20200157171A1 (en) 2020-05-21
EP3655006A1 (en) 2020-05-27
JP2024045117A (ja) 2024-04-02
JP7417277B2 (ja) 2024-01-18
LT4186920T (lt) 2024-04-25
HRP20230991T1 (hr) 2023-12-08

Similar Documents

Publication Publication Date Title
LT4011908T (lt) Itin ilgai veikiantys insulino-fc sulieti baltymai ir naudojimo būdai
LT4073098T (lt) Itin ilgai veikiantys insulino-fc sulieti baltymai ir jų naudojimo būdai
IL288373A (en) flt3l-fc fusion proteins and methods of use
IL280102A (en) Fusion protein containing PD1-4-1BBL and methods of using it
LT3601358T (lt) Anti-trem2 antikūnai ir jų naudojimo metodai
PL3565828T3 (pl) Białko fuzyjne SIRP1 ALFA-41BBL i sposoby jego zastosowania
PL3445787T3 (pl) Kompozycje i sposoby reprogramowania receptorów limfocytów t przy użyciu białek fuzyjnych
LT3618863T (lt) Anti-tigit antikūnai ir jų panaudojimo būdai
DK3565579T3 (da) Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
IL255697A (en) Compositions and methods for tcr reprogramming using fusion proteins
SG11202006259SA (en) Il-22 fc fusion proteins and methods of use
LT3618928T (lt) Anti-sortilino antikūnai ir jų panaudojimo būdai
IL280103A (en) Fusion protein containing SIRPalpha-4-1BBL and methods of using it
IL264528B1 (en) Fcrn antibodies and methods of use thereof
DK3177307T3 (da) Interleukin-2/interleukin-2 receptor-alpha-fusionsproteiner og fremgangsmåder til anvendelse
LT3525583T (lt) Anti-c1s antikūnai ir jų naudojimo būdai
IL281641A (en) Methods and uses of variant cd80 fusion proteins and related constructs
DK3431507T5 (da) Fusionsprotein omfattende nervevækstfaktor og fremstillingsfremgangsmåde og anvendelse deraf
EP3895023A4 (en) MACRO OP FUSION
PT3387019T (pt) Proteínas de fusão de imunoglobulina de relaxina e métodos de uso
EP3688037A4 (en) IMMUNOMODULATOR FUSION PROTEINS
EP3668551A4 (en) APOM-FC FUSION PROTEINS AND THEIR USES
DK3158058T3 (da) Fusionsproteiner og bruger deraf
EP3763817A4 (en) FLAVINE FUSION PROTEIN ADENINE DINUCLEOTIDE-GLUCOSE DEHYDROGENASE AND CYTOCHROME MOLECULE
HK40050153A (en) Sirpalpha-4-1bbl variant fusion protein and methods of use thereof